GreatGigz Solutions v. Christus Health: Dismissal With Prejudice in Healthcare Web Platform Patent Case

After nearly four years of litigation before the Western District of Texas, GreatGigz Solutions, LLC v. Christus Health (Case No. 6:21-cv-01310) concluded with a court-ordered dismissal of all patent infringement claims with prejudice — a decisive outcome favoring the defendant. Filed in December 2021, the case centered on allegations that Christus Health’s patient-facing web platform infringed an expansive portfolio of 18 patents spanning workforce management, data processing, and digital communication technologies.

The resolution — driven by the plaintiff’s own motion to dismiss following a court-imposed stay — carries significant implications for healthcare technology patent litigation, multi-patent assertion strategies, and the increasingly complex interplay between USPTO post-grant proceedings and district court scheduling. For patent attorneys, in-house IP counsel, and R&D teams operating in the digital health space, this case offers a textbook study in litigation risk, portfolio assertion tactics, and the strategic consequences of a stayed case ultimately abandoned by the asserting party.

Case Overview

The Parties

The Patents at Issue

The plaintiff asserted 18 patents, including:

• • US9760864B2 – Web-based platform systems
• • US10096000B2 – Online service matching and scheduling
• • US6662194B1 – Data management and retrieval systems
• • US6381592B1 – Data management and retrieval systems
• • US6363376B1 – Data management and retrieval systems
• • US7490086B2 – Digital communication infrastructure
• • US7148991B2 – Digital communication infrastructure
• • US20060190661A1
• • US4625081A
• • US5978768A
• • US6385620B1
• • US5164897A
• • US6873964B1
• • US6324538B1
• • US6567784B2
• • US6370510B1
• • US5832497A
• • US6332125B1

These patents span multiple technology generations, from early 1990s data processing innovations to mid-2000s web platform architectures — a hallmark of broad NPE portfolio assertions.

The Accused Product

The accused product was Christus Health’s patient web portal hosted at www.christushealth.org, specifically its Patient Portal functionality. The plaintiff alleged that the platform — encompassing memory, processors, transmitters, and receivers — infringed across multiple patent claims related to digital matching, scheduling, and communication systems.

Legal Representation

Plaintiff’s counsel: M. Scott Fuller, Randall T. Garteiser, and Rene A. Vazquez of Garteiser Honea PLLC and DNL Zito — firms with active NPE litigation practices.

Defendant’s counsel: A nine-attorney team drawn from DLA Piper LLP (US), Quarles & Brady LLP, Cherry Johnson Siegmund James PLLC, and Steckler Wayne Cherry & Love PLLC, reflecting the institutional resources Christus Health deployed to defend this multi-patent assertion.

Litigation Timeline & Procedural History

The case ran for 1,373 days — approximately 3 years and 9 months — before resolution in the Western District of Texas under Chief Judge Alan D. Albright, a jurist nationally recognized for his patent-friendly docket management and high volume of patent cases. Judge Albright’s court has been a preferred venue for NPE plaintiffs due to its specialized patent procedures and scheduling efficiency, though ongoing judicial reforms have modestly reshaped that calculus.

A critical procedural event was the **court-imposed stay** (Dkt. 34), almost certainly triggered by parallel USPTO post-grant proceedings — likely inter partes review (IPR) petitions targeting one or more of the 18 asserted patents. The stay’s existence and the plaintiff’s subsequent decision to seek dismissal rather than resume litigation strongly suggests that post-grant proceedings eroded the viability of the asserted patent claims.

The Verdict & Legal Analysis

Outcome

On September 19, 2025, the Court granted Plaintiff GreatGigz Solutions, LLC’s motion to lift the stay and dismiss all claims against Christus Health with prejudice. The Court simultaneously designated Christus Health as the prevailing party, entitling it to an award of costs. Final judgment was ordered to follow by separate order.

Critically, this was a plaintiff-initiated dismissal with prejudice — meaning GreatGigz itself moved to end the case permanently, foreclosing any future re-assertion of these specific claims against Christus Health. No damages were awarded to the plaintiff. No injunctive relief was granted.

Verdict Cause Analysis

The dismissal with prejudice following a prolonged stay is a pattern consistent with IPR or post-grant proceedings significantly weakening asserted patent claims. When the USPTO cancels or narrows patent claims during inter partes review, NPE plaintiffs frequently lack viable infringement theories upon return to district court, making voluntary dismissal the rational outcome.

The sheer breadth of the asserted portfolio — 18 patents, many dating to the 1990s — itself signals a high-volume assertion strategy that relies on licensing pressure rather than technically specific infringement allegations. Defendants facing such assertions increasingly file IPR petitions across multiple asserted patents simultaneously, forcing plaintiffs to defend claim validity on multiple fronts. Christus Health’s nine-attorney defense team, including DLA Piper’s national IP practice, was well-positioned to execute this strategy.

The “prevailing party” designation is strategically significant: it opens the door to a potential exceptional case finding under 35 U.S.C. § 285, which could expose GreatGigz to an attorney’s fees award — a risk that may have itself accelerated the plaintiff’s decision to seek dismissal.

Legal Significance

This case reinforces several important doctrinal and strategic points in contemporary patent litigation:

1. Post-grant proceedings remain the most effective defensive tool against NPE multi-patent assertions. A stay pending IPR or PGR effectively freezes litigation costs while USPTO proceedings resolve validity questions that directly undermine plaintiffs’ leverage.
2. Prevailing party status in dismissals with prejudice matters. Courts have increasingly recognized that defendants who successfully defend through dismissal — even plaintiff-initiated — may qualify as prevailing parties for cost and fee purposes.
3. Broad portfolio assertions carry inherent vulnerability. Asserting 18 patents increases the probability that at least several claims are invalidated through post-grant review, collapsing the economic rationale for continued litigation.

Industry & Competitive Implications

The healthcare technology sector continues to attract NPE patent assertions, driven by accelerating digital transformation — patient portals, telehealth integration, and AI-assisted scheduling platforms all present expanded target surfaces for broad internet-patent portfolios.

This case reflects a broader industry trend: healthcare providers are increasingly targets of software and internet patent assertions as their digital infrastructure scales. Unlike technology companies, healthcare systems have historically underinvested in patent defense infrastructure, making them attractive targets. However, as demonstrated here, well-resourced defense teams leveraging post-grant proceedings can neutralize even large-scale assertions.

For the digital health sector, the case signals that legacy internet patents — even those dating to the 1990s — remain litigation tools that IP teams must monitor. Companies investing in patient portal technology, scheduling platforms, or web-based healthcare services should proactively audit their technology stack against aging but still-active patent portfolios held by assertion entities.

The multi-firm defense strategy employed by Christus Health — coordinating national firms (DLA Piper, Quarles & Brady) with regional Texas counsel — represents an increasingly common and effective model for healthcare defendants in WDTX patent litigation.

FAQ

What patents were involved in GreatGigz Solutions v. Christus Health?

Eighteen U.S. patents were asserted, including US9760864B2, US10096000B2, US6662194B1, and US7490086B2, covering web platform, data processing, and digital communication technologies. The full list is available via PACER Case No. 6:21-cv-01310 and the USPTO Patent Center.

Why were the claims dismissed with prejudice?

The plaintiff moved to dismiss following a court-imposed stay, most likely reflecting the outcome of parallel USPTO post-grant proceedings that undermined the viability of the asserted patent claims.

How does this affect healthcare technology patent litigation?

The case underscores that healthcare providers face ongoing NPE assertion risk on digital platforms and that aggressive use of IPR proceedings remains the most effective defense strategy.